Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

PHASE4TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

Dextenza 0.4Mg Ophthalmic Insert

All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.

DRUG

Prednisolone Acetate

All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).

Trial Locations (1)

33711-1141

Retina Vitreous Associates of Florida, St. Petersburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Retina Vitreous Associates of Florida

OTHER

NCT04563299 - Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections | Biotech Hunter | Biotech Hunter